Platelet Transfusion Risks and Management

Immediate Life-Threatening Complications

• TRALI is a leading cause of transfusion-related mortality and presents as acute lung injury within 6 hours of transfusion with hypoxemia, respiratory distress, dyspnea, bilateral pulmonary infiltrates, and fever 3, 4
• Fresh frozen plasma (FFP) and platelet concentrates are the blood products most frequently implicated in TRALI 3, 4
• The mechanism involves donor leukocyte antibodies (HLA class I, class II, or granulocyte-specific) interacting with recipient neutrophils 4
• Stop the transfusion immediately when TRALI is suspected and provide critical care respiratory support—do NOT give diuretics as they are ineffective and may worsen the condition 3, 4
• Blood banks now screen donors for leukocyte antibodies and preferentially use male-only plasma donors to reduce TRALI risk 4
• TACO is now the most common cause of transfusion-related mortality, occurring during or up to 12 hours after transfusion 4
• Presents with acute respiratory compromise, pulmonary edema, cardiovascular changes (hypertension, tachycardia), and evidence of fluid overload 4
• Patients at highest risk include those over 70 years old, non-bleeding patients, and those with heart failure, renal failure, or hypoalbuminemia 4
• Treatment requires immediate cessation of transfusion and diuretic therapy (in contrast to TRALI) 4
• Bacterial contamination should be suspected if patients experience severe febrile reactions during or shortly after platelet transfusions 5
• Storage at 20°C to 24°C creates conditions that permit bacterial growth, making platelets the blood product with highest contamination risk 5
• Storage time is limited to 5 days (or 7 days with bacterial detection testing or pathogen reduction technologies) to minimize this risk 5, 6
• Stop the transfusion immediately, obtain blood cultures from both patient and blood product, and strongly consider empiric antibiotics, particularly in neutropenic recipients 5, 6

Common Adverse Reactions

• Febrile or allergic transfusion reactions are among the most common side effects of platelet transfusion 1, 2
• Repeated platelet transfusions induce alloantibodies in recipients, potentially resulting in platelet transfusion refractoriness (PTR) 7
• The incidence of alloantibody-mediated refractoriness can be decreased in patients with acute myeloid leukemia when both platelet and RBC products are leukoreduced before transfusion 7
• Prestorage leukoreduction is recommended from the time of diagnosis to ameliorate this problem 7
• Leukoreduction also substantially reduces transfusion reactions and transmission of cytomegalovirus (CMV) infection 7

Additional Serious Complications

• Transfusion-Associated Graft-Versus-Host Disease is a rare but usually fatal complication resulting from transfusion of viable lymphocytes capable of immune attack against the recipient 5
• Prevention requires pretransfusion gamma irradiation of blood products for high-risk patients including stem-cell transplant recipients, those receiving blood from partially matched family members, and patients with severe immunosuppression (e.g., Hodgkin's lymphoma) 5
• Leukocyte depletion alone does not eliminate this risk 5
• Rare hemolytic reactions can occur due to incompatible plasma, particularly when O donor platelets are transfused to A or B recipients 5
• ABO-compatible products should be provided whenever possible, though clinically significant hemolysis is unusual in adult recipients 5
• All platelet products are tested for required transfusion-transmitted diseases 5
• Pathogen reduction technologies using UV irradiation with photosensitizers are now available and approved to further decrease infection transmission risk 5

Risk Mitigation Strategies

• To minimize adverse effects, clinicians should use leukoreduced blood products universally 7
• Provide ABO-compatible platelets when possible 5
• Irradiate products for immunocompromised patients 5
• Transfuse single units in non-hemorrhaging patients and reassess before additional units 4
• Monitor vital signs closely during and after transfusion 3
• Report all suspected transfusion reactions immediately to the blood bank 6
• Consider pathogen-reduced platelet products when available 5